<?xml version="1.0" encoding="UTF-8"?>
<ref id="r84">
 <label>84</label>
 <mixed-citation publication-type="journal">
  <string-name>
   <surname>Liu</surname>
   <given-names>TJ</given-names>
  </string-name>, 
  <string-name>
   <surname>Koul</surname>
   <given-names>D</given-names>
  </string-name>, 
  <string-name>
   <surname>LaFortune</surname>
   <given-names>T</given-names>
  </string-name>, 
  <string-name>
   <surname>Tiao</surname>
   <given-names>N</given-names>
  </string-name>, 
  <string-name>
   <surname>Shen</surname>
   <given-names>RJ</given-names>
  </string-name>, 
  <string-name>
   <surname>Maira</surname>
   <given-names>SM</given-names>
  </string-name>, 
  <string-name>
   <surname>Garcia-Echevrria</surname>
   <given-names>C</given-names>
  </string-name>, 
  <string-name>
   <surname>Yung</surname>
   <given-names>WK</given-names>
  </string-name>. 
  <article-title>NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.</article-title>
  <source>Mol Cancer Ther</source>. 
  <year>2009</year>; 
  <volume>8</volume>:
  <fpage>2204</fpage>â€“
  <lpage>10</lpage>. 
  <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0160</pub-id>
  <?supplied-pmid 19671762?>
  <pub-id pub-id-type="pmid">19671762</pub-id>
 </mixed-citation>
</ref>
